Intetumumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | integrin alpha-V |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6468H10008N1744O2006S40 |
| Molar mass | 145579.81 g·mol−1 |
  (what is this?) (verify) | |
Intetumumab is a human monoclonal antibody targeting integrins[1] that was being studied for the treatment of solid tumors.[2]
Intetumumab was developed by
Centocor
, Inc.
Phase II clinical trials for treatment of melanoma and prostate cancer were in progress when development of the drug was discontinued.[3]
References
- S2CID 53952455.
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab" (PDF). American Medical Association.
- ^ "Intetumumab". AdisInsight. Retrieved 30 January 2017.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |